Residual disease in children with ALL at different time points during the first 6 months of treatment according to the ALL-BFM 95 protocol
| Time point . | No. patients with MRD vs tested samples* (%) . | Median % (range)† of leukemic cells . | Blasts/μL BM† median (range) . |
|---|---|---|---|
| d 15 | 90/101 (89.1) | 0.57 (0.002-96.8) | 17.8 (0.1-18 295) |
| d 33 | 43/105 (40.9) | 0.06 (0.001-43.1) | 4.0 (0.1-3 235) |
| wk 12 | 7/51* (13.7) | 0.057 (0.001-4.9) | 10.4 (0.53-820) |
| wk 22-24 | 2/47* (4.3) | 0.023 (0.004-0.5) | 6.8 (0.2-13.1) |
| Time point . | No. patients with MRD vs tested samples* (%) . | Median % (range)† of leukemic cells . | Blasts/μL BM† median (range) . |
|---|---|---|---|
| d 15 | 90/101 (89.1) | 0.57 (0.002-96.8) | 17.8 (0.1-18 295) |
| d 33 | 43/105 (40.9) | 0.06 (0.001-43.1) | 4.0 (0.1-3 235) |
| wk 12 | 7/51* (13.7) | 0.057 (0.001-4.9) | 10.4 (0.53-820) |
| wk 22-24 | 2/47* (4.3) | 0.023 (0.004-0.5) | 6.8 (0.2-13.1) |
Data of consecutively tested patients (ie, first half of the study cohort).
Data of all available MRD+ testings included (week 12, n = 13; weeks 22-24, n = 6; ie, from MRD+ patients of the first half of the study cohort, and from later enrolled patients who were tested only if MRD+at the preceding time point).